Not available
Quote | ChemoCentryx Inc. (NASDAQ:CCXI)
Last: | $51.99 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $51.99 |
High: | $0 |
Low: | $0 |
Volume: | 113 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | ChemoCentryx Inc. (NASDAQ:CCXI)
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
ChemoCentryx shareholders have overwhelmingly approved Amgen's ( NASDAQ: AMGN ) $3.7B acquisition of the compan y. With the acquisition, Amgen ( AMGN ) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoanti...
Message Board Posts | ChemoCentryx Inc. (NASDAQ:CCXI)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CCXI News Article - ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcomin | whytestocks | investorshangout | 08/24/2022 12:40:56 PM |
whytestocks: $CCXI News Article - SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates MV | whytestocks | investorshangout | 08/19/2022 12:55:51 PM |
whytestocks: $CCXI News Article - ChemoCentryx Cancels Second Quarter 2022 Financial Results Confere | whytestocks | investorshangout | 08/09/2022 12:35:59 PM |
whytestocks: $CCXI News Article - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of | whytestocks | investorshangout | 08/04/2022 8:25:55 PM |
I have some in family ties. I cant pm. | bbartgen | investorshub | 04/06/2022 12:59:22 PM |
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...